Anavex Life Sciences (AVXL) Non Operating Income (2016 - 2025)

Anavex Life Sciences has disclosed Non Operating Income across 10 years of filings, most recently posting $1.1 million for Q4 2025.

• Non Operating Income for Q4 2025 came in at $1.1 million, down 24.44% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.7 million (down 45.7% YoY), and the FY2025 annual result was $5.0 million, down 49.05% from the prior year.
• Non Operating Income came in at $1.1 million for Q4 2025 at Anavex Life Sciences, up from $1.0 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $2.8 million in Q4 2023 to a low of $179800.0 in Q2 2022.
• The 5-year median for Non Operating Income is $1.2 million (2021), against an average of $1.5 million.
• Across the five-year window, Non Operating Income slumped 85.7% in 2022 and jumped 1174.75% in 2023, its largest moves.
• Anavex Life Sciences' Non Operating Income stood at $871003.0 in 2021, then surged by 174.63% to $2.4 million in 2022, then increased by 15.22% to $2.8 million in 2023, then tumbled by 46.26% to $1.5 million in 2024, then retreated by 24.44% to $1.1 million in 2025.
• The last three Non Operating Income figures came in at $1.1 million (Q4 2025), $1.0 million (Q3 2025), and $1.2 million (Q2 2025), per Business Quant data.